Granza Bio
Winter 2024Reprogramming Immunity for Target-Specific Medicines
Synthetic BiologyBiotechHealthcareTherapeuticsOncology
About Company
Granza Bio is building on the discovery of a previously unknown cytotoxic mechanism in T cells: supramolecular attack particles (SMAPs, Science 2020). This biology reveals a new modality through which cytotoxic lymphocytes deliver persistent, high-intensity killing.
Active Founders
Ashwin completed his PhD (DPhil) in Oncology at the University of Oxford. After completing his PhD, he began working as a Cancer Research UK post-doctoral researcher at Oxford University and also at the Institute of Cancer Research (ICR), London. He also brings experience setting up oncology clinical trials and working in oncology start-ups.
